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Abstract
The most common endocrinopathy associated with McCune-Albright Syndrome (MAS) is 
peripheral precocious puberty (PP) which occurs far more often in girls than in boys. We will 
discuss the latest advancements in the treatment of precocious puberty in MAS that have been 
achieved during the past 10 years. However, due to the rarity of the condition and the 
heterogeneity of the disease, research in this field is limited particularly in regards to treatment in 
boys. In girls, a period of watchful waiting is recommended prior to initiating therapy due to 
extreme variability in the clinical course. This article will review in detail current pharmacologic 
treatment in girls, which typically consists of either inhibiting estrogen production or blocking 
estrogen action at the level of the end-organ. The two treatments with the most evidence at this 
time are Tamoxifen (which is an estrogen receptor modulator) and Letrozole (which is a 3rd 
generation aromatase inhibitor). This article will also review the current treatment strategies in 
boys which typically include using an androgen receptor blocker and an aromatase inhibitor. Due 
to the rarity of the condition, large multicenter collaborative studies are needed to further 
investigate efficacy and safety with the goal of establishing the gold standard for treatment of PP 
in children with MAS.
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Introduction
McCune-Albright syndrome (MAS) is a rare genetic disorder with a prevalence of between 
1:100,000 and 1:1,000,000 (1). It is caused by an activating post-zygotic somatic mutation in 
the GNAS1 gene which leads to increased GSa protein signaling. This results in continuous 
activation of adenyl cyclase leading to increased cAMP and ligand independent 
amplification of the downstream effects (1,2). MAS is classically characterized by the triad 
of fibrous dysplasia of bone (classic x-ray finding is of a hazy, radiolucent, “ground glass 
appearance”), café-aulait skin pigmentation, and peripheral precocious puberty (PP) (1,3,4). 
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However, there are other associated endocrinopathies including hyperthyroidism, Cushing 
syndrome, GH excess and renal phosphate wasting (2) in addition to rare cases of 
widespread multi-systemic involvement (5). This review will provide an update of the 
treatment of PP in children with MAS with a focus on knowledge that has accumulated 
during the last ∼10 years.
Precocious Puberty in Girls
Girls with MAS are much more likely to develop PP than boys. Affected girls have 
autonomously functioning unilateral ovarian cysts which lead to significantly high serum 
estradiol concentrations with suppressed gonadotropins (2,6). In patients with classic MAS, 
a single suppressed LH may be sufficient for the diagnosis. Girls with PP typically present in 
early childhood with painless vaginal bleeding which may be profuse, and minimal if any 
breast development (it may have resolved by the time the patient is seen). PP is typically the 
first manifestation of the disorder, and in atypical cases it may be the only feature (2,6). 
Therefore, it is important to evaluate patients who present with an isolated autonomous 
ovarian cyst for MAS (7). If the evaluation is consistent with MAS, the patient should have a 
bone scan to evaluate for fibrous dysplasia as well as laboratory tests to screen for other 
endocrinopathies. Genetic testing for a GNAS1 mutation is available. However, due to the 
mosaic nature of the mutation, it may be falsely negative in peripheral blood. The likelihood 
of finding a mutation improves substantially if affected tissue is analyzed (2). There is a high 
variability in the clinical course of girls with MAS and PP. While some girls have repeated 
episodes of estrogen exposure leading to frequent vaginal bleeding, advanced bone age and 
growth acceleration, others have extended periods of disease inactivity (2). Thus, an initial 
period of observation prior to pharmacologic intervention is recommended following a new 
diagnosis of MAS and PP. Interestingly, periodic autonomously functioning ovarian cysts 
continue to occur in the post-pubertal years and may result in irregular bleeding and 
prolonged hyperestrogenism in adolescent and adult women with MAS (8).
Treatment in Girls
Various therapies have been used to treat PP in affected girls. The goal of treatment is to 
decrease estrogen exposure with the objective of preventing vaginal bleeding, halting 
pubertal progression and improving adult height. GnRH analogs as a primary intervention 
are not successful due to the fact that the HPG axis is not involved in the sex steroid 
production in peripheral PP. However, over time many patients develop secondary central PP 
at which point the addition of a GnRH analog is beneficial (9).
In the past, cyproterone acetate and medroxyprogesterone demonstrated short term efficacy 
in controlling vaginal bleeding and breast development. In contrast, neither agent has been 
shown to influence growth rates or adult height, and are therefore considered inadequate for 
the treatment of PP in girls with MAS (2,10,11). The current therapeutic armamentarium is 
comprised of medications that either inhibit estrogen biosynthesis or block its effects at the 
level of the end organ. It should be noted that periodic episodes of autonomous ovarian 
function continue regardless of treatment status since anti-estrogen therapy has no impact on 
the underlying pathophysiology of the disease. The extreme rarity of the condition and the 
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pleomorphic nature of its clinical manifestations represent important obstacles to rigorous 
investigation of therapeutic strategies for PP. Regardless, important insights pertaining to a 
number of medications have been gleaned from case reports, non-randomized prospective 
studies (in which girls function as their own controls) and limited long-term retrospective 
follow-up. Available data regarding each of these is discussed in the following section while 
studies published since 2007 are summarized in Table 1.
Ketoconazole is a non-specific inhibitor of cytochrome p450 enzymes and so can block both 
adrenal and gonadal steroidogenesis (12). It was used successfully in 2 girls with MAS in 
whom it caused cessation of menstrual cycles, regression of secondary sexual characteristics, 
decreased estradiol levels and attenuated bone age advancement (12). However, there is 
concern regarding long term safety with ketoconazole due to the risk of adrenal insufficiency 
and hepatotoxicity (13). Therefore, no prospective studies involving ketoconazole for the 
treatment of PP in girls with MAS have been pursued (12).
Aromatase inhibitors inhibit aromatase which is the enzyme that converts androgens to 
estrogens (14). This class of medications is used in both girls and boys with forms of 
peripheral PP. Testolactone (which is a 1st generation aromatase inhibitor) was initially 
attempted and found to be minimally successful. One study followed 12 girls treated for 0.5–
5 years, 7 of whom received testolactone for at least 3 years. Although reductions in serum 
estradiol levels and frequency of vaginal bleeding were noted, mean predicted adult heights 
were not significantly improved after treatment. Positive results were most evident in the 
first year, consistent with an escape phenomenon of the medication (15). Additionally, 
testolactone requires being dosed 4 times a day, and so it is not routinely used (16).
Fadrazole is a 2nd generation aromatase inhibitor, although it is not specific to aromatase, as 
previous studies in adults have shown a blunting of cortisol and aldosterone (17). One study 
involved 16 girls who were treated with fadrazole and did not find it to be effective. In the 
group as a whole, there was no significant decrease in skeletal maturation, mean growth rate 
SDS or predicted adult height. Likewise, there was no significant decrease in mean estradiol 
levels or mean ovarian volumes. While vaginal bleeding decreased initially, this was not 
sustained. There was also a dose dependent decrease in cortisol and an increase in renin 
activity level. Three patients were found to have biochemical evidence of adrenal 
insufficiency and were started on hydrocortisone replacement. In 2 girls the adrenal axis 
returned to normal after discontinuation of the medication whereas the 3rd continued to have 
mild adrenal insufficiency. Due to lack of effectiveness for the group as a whole and the 
concern for side effects, newer aromatase inhibitors with greater potency and specificity 
were studied (17).
Anastrozole is a 3rd generation aromatase inhibitor. A prospective, international, multi-
institutional trial was conducted in 28 girls for one year with disappointing results. The 
study found no difference in bone age advancement, frequency of vaginal bleeding, or mean 
ovarian or uterine volumes with treatment. While growth velocity z-scores did decrease, this 
was not statistically significant. Although anastrozole appeared safe in the study, its lack of 
efficacy renders it a poor choice for the treatment of PP in girls with MAS (18).
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Letrozole is a potent long-acting 3rd generation aromatase inhibitor (19). An initial pilot 
study in 9 girls with MAS who were treated for up to 36 months was conducted. The study 
found a significant decrease in growth velocity SDS (p=≤0.01) and bone age maturation 
(p=≤0.004). Mean serum estradiol and ovarian volumes fell at 6 months but usually 
increased by 12–24 months, although these changes did not reach statistical significance. Six 
of the 9 girls stopped having vaginal bleeding and 3 others had a reduction in the frequency 
of bleeds. The therapy was well tolerated, although 1 patient developed a large ovarian cyst 
with torsion that required surgical intervention, representing a potential safety signal related 
to the use of letrozole in this clinical population (19).
Results from a single-center retrospective cohort study of 28 girls including the 9 from the 
initial pilot study who received at least 6 months of letrozole treatment have been published. 
Rates of bone age maturation and mean growth velocity z-scores significantly decreased and 
there was a significant increase in predicted adult height z-scores (20). In the 4 patients who 
had reached adult height, the mean z-score was statistically increased in comparison with 
untreated historical controls. Vaginal bleeding episodes and estradiol levels decreased, and 
there was no change in uterine or ovarian volumes. No adverse events were reported during 
the study period, including no further incidents of ovarian torsion. In conclusion this study 
found that unlike other aromatase inhibitors, letrozole appears to be an effective treatment 
for MAS associated PP that is also likely safe (20).
Another class of medications that has been used in girls with MAS-associated PP are 
estrogen receptor modulators such as tamoxifen. A multicenter prospective study was 
performed in 28 girls who were treated for 1 year. Episodes of vaginal bleeding decreased 
and a significant reduction in growth velocity SDS and rates of bone maturation was 
observed. No adverse effects were reported although uterine volumes increased during 
treatment with tamoxifen. Thus, periodic pelvic ultrasounds are recommended in girls 
treated with this modality due to theoretical concerns about tamoxifen associated stromal 
tumors although none have been reported in the setting of MAS to date (21).
A retrospective follow-up study in 8 patients treated with tamoxifen for 3–8 years and 
monitored for a mean period of 8.3 years (range 3–16 years) was reported. All had cessation 
of vaginal bleeding and stabilization of bone maturation. A significant difference between 
the predicted adult height (PAH) at the beginning of treatment and at the end of treatment 
was also observed (22). However, final heights in the 4 patients who had completed growth 
was less than predicted, although only 1 had an adult height below 2 standard deviations. 
Tamoxifen was well tolerated, with no adverse effects noted, including no changes in bone 
mineral density (BMD) or alterations in the uterine endometrium. In conclusion the results 
support a role for tamoxifen in treating PP and improving PAH in girls with MAS, albeit the 
effect on adult height may not be as robust in follow-up as initially predicted (22).
Fulvestrant is a pure estrogen receptor blocker that is administered via monthly 
intramuscular injection. An international, prospective study enrolled 30 girls who were 
treated for 1 year. Median annual vaginal bleeding days decreased from 12.0 to 1.0 with a 
median change in frequency of 3.6 days (p=0.0146) (23). The ratio of bone age to 
chronological age also significantly decreased. There was no statistically significant change 
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in mean growth velocity z-scores and no change in PAH. There was no significant change in 
uterine size. The most common adverse reaction was at the site of injection. The authors 
concluded that longer treatment with fulvestrant might have led to improved PAH, as there 
was a progressive decrease in bone age advancement throughout the study (23).
Surgery (including cystectomy or oophorectomy) is not recommended due to the cysts likely 
recurring and concerns about a negative impact on fertility (2). Unfortunately, unnecessary 
oophorectomy has been reported due to a failure to include MAS in the differential diagnosis 
of a prepubertal girl presenting with sudden onset of vaginal bleeding and an apparent 
ovarian mass (24).
Precocious Puberty in Boys
PP is uncommon in boys with MAS. It is caused by Leydig cell hyperplasia and increased 
testosterone production which in turn leads to a premature increase in penile size and mild 
bilateral testicular enlargement (2). Labs demonstrate elevated serum testosterone and 
suppressed gonadotropins.
Cases in which a Sertoli cell only GNAS1 activating mutation is present have been reported 
and result in unilateral or bilateral macroorchidism without PP (25). A prospective cohort 
study with 54 subjects was undertaken to evaluate the spectrum of testicular pathology in 
boys with MAS. The authors found that 44% of the subjects with a recorded testicular 
volume had asymptomatic macroorchidism which was usually bilateral. Interestingly 81% of 
the subjects had testicular abnormalities on ultrasound, the most common of which were 
hyperechoic lesions, but hypoechoic lesions, microlithiasis, heterogeneity, and focal 
calcifications were also seen (26). Twenty-one percent of this cohort presented with PP. The 
investigators concluded that even though the incidence of PP is low in boys with MAS, the 
incidence of gonadal involvement is the same between the genders (26). In boys who had an 
indication for surgical excision the predominant finding was Leydig cell hyperplasia (LCH) 
which carries a low risk for malignant transformation. Of note however, is that one subject 
developed bilateral germ cell tumors. Based on these findings, the authors recommend 
following testicular lesions conservatively through close observation and serial imaging with 
the goal of testicular preservation (26).
Treatment in Boys
There are limited data regarding treatment of PP in boys with MAS. The most common 
approach is to use an androgen receptor blocker and an aromatase inhibitor as is the case in 
other forms of peripheral PP in boys (2,25). The goal of treatment is to slow virilization with 
the ultimate aim of improving final height. Given the scarcity of affected boys, available 
information is primarily derived from isolated case reports.
Combination therapy was successful in a single case involving a boy with MAS who was 
treated with the antiandrogen bicalutamide and anastrozole. He was initially diagnosed with 
PP at 4.6 years old. He was treated with bicalutamide 25mg/day and anastrozole 1mg/day 
for 49 months (3). His growth velocity and penile length decreased, and there were no signs 
of progression of secondary sexual characteristics or gynecomastia. There was a rapid 
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reduction in masturbatory behaviors and frequency of erections. Bone age was equal to 
chronological age at the end of the follow-up period. The therapy was well tolerated, LFTs 
remained normal, and there was no modification of BMD (3).
Another case report described a boy with atypical MAS who was treated with the 
combination of ketoconazole, cyproterone acetate and leuprolide. He was 4.6 years when he 
presented with unilateral macroorchidism with no signs of PP. Initially he was followed over 
time. He then developed PP and at 6.6 years he was started on ketoconazole (400mg/daily in 
2 divided doses) and cyproterone acetate (50mg/daily). During the first 12 months the size of 
his right testicle decreased, there was a decrease in testosterone and a significant 
deceleration of growth velocity and rate of skeletal maturation (27). However, during the 2nd 
year of treatment the changes were not as pronounced, likely due to the fact that he had 
entered central puberty. He was then started on leuprolide. During the next 4.2 years a 
decline in growth velocity and bone maturation were again noted. Therapy was stopped at 13 
years and central puberty ensued. There were no reported side effects and no changes in 
transaminase levels. His adult height (188.5cm) exceeded his target height (181.2cm) and 
was close to the predicted height at the start of treatment (191.8cm) (27).
Conclusion
In summary, important strides have been made in the treatment of PP in girls and boys with 
MAS since 2007. Particularly in view of information pertaining to long-term follow-up, both 
letrozole and tamoxifen have emerged as favorable options for first-line treatment in girls. 
Despite these advances, there remains a need for research in this condition, especially in 
boys. Due to the rarity of the disorder, collaborative, multicenter, prospective studies are 
essential in order to confirm efficacy and safety and establish a gold standard for treatment.
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